1,306
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer

&

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Mohamad Moussa, Athanasios Papatsoris, Mohamed Abou Chakra, Despoina Sryropoulou & Athanasios Dellis. (2020) Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy 21:12, pages 1431-1448.
Read now
Athanasios Dellis & Athanasios Papatsoris. (2016) Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 5-10.
Read now
Athanasios Dellis & Athanasios G Papatsoris. (2014) The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 14:2, pages 175-179.
Read now

Articles from other publishers (3)

Yuya Hirano & Yasuhiko Iwasaki. (2017) Bone-specific poly(ethylene sodium phosphate)-bearing biodegradable nanoparticles. Colloids and Surfaces B: Biointerfaces 153, pages 104-110.
Crossref
Michael P. Hoeh & Leslie A. Deane. (2014) PSA Screening: A Discussion Based on the USPSTF Recommendations and the AUA and EAU Guidelines. Journal of Men's Health 11:1, pages 10-17.
Crossref
Johanna Tuomela & Pirkko Härkönen. (2014) Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression. Reproductive Biology 14:1, pages 16-24.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.